Frontiers in ImmunologyBioinformaticsPeer-reviewed journal article
Computational pipeline for the PGV-001 neoantigen vaccine trial
Alex RubinsteyniD, Julia KodyshiD, Isaac HodesiD, Sébastien MondetiD, Bülent Arman AksoyiD, John P. FinniganiD, Nina BhardwajiD, Jeff HammerbacheriD
Abstract
This paper describes the sequencing protocol and computational pipeline for the PGV-001 personalized vaccine trial. PGV-001 is a therapeutic peptide vaccine targeting neoantigens identified from patient tumor samples. Peptides are selected by a computational pipeline which identifies mutations from tumor/normal exome sequencing and ranks mutant sequences by a combination of predicted Class I MHC affinity and abundance estimated from tumor RNA. The PGV pipeline is modular and consists of many independently usable tools and software libraries. We draw attention to three particular tools which may be useful to other groups working on neoantigen vaccination. (1) Epidisco is a workflow which orchestrates the parallel execution of the PGV pipeline, including both common steps such as alignment as well as tools which have been developed specifically for the PGV-001 trial. (2) Vaxrank uses somatic variants and tumor RNA reads to select peptides for inclusion in a patients vaccine. (3) Isovar is a library used by Vaxrank to determine the mutated protein sequence associated with a genomic variant from supporting tumor RNA reads. We hope that the functionality of these tools may extend beyond the specifics of the PGV-001 trial and enable other research groups in their own neoantigen investigations.
- organism: human
- assay: whole-exome sequencing
- assay: bulk RNA-seq
- research focus: variant calling
- research focus: differential expression
- research focus: software / tool
- approach: statistical model
- Citations
- 74
- FWCI
- 2.49
- Field percentile
- top 9%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- In vitro validation of neoantigen prediction algorithm for developing personalized cancer vaccine therapy
Y.-j. Choe, E. Kim, … S. Paik·bioRxiv·Dec 12, 2021
- Vaxrank: A Computational Tool For Designing Personalized Cancer Vaccines
Alex Rubinsteyn, Isaac Hodes, … Jeff Hammerbacher·bioRxiv·Oct 18, 2018
- VLP-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice
A. Barajas, P. Amengual-Rigo, … J. Blanco·bioRxiv·Sep 7, 2023
- pVACtools: a computational toolkit to identify and visualize cancer neoantigens
Jasreet Hundal, Susanna Kiwala, … Malachi Griffith·Cancer Immunology ResearchPeer-reviewed·Jan 6, 2020
- A modular, immunopeptidogenomic (iPepGen) analysis pipeline for discovery, verification, and prioritization of cancer peptide neoantigen candidates
Subina Mehta, Reid Wagner, … Timothy J. Griffin·Genome biologyPeer-reviewed·Feb 25, 2026
- Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma
M. O. Mohsen, D. E. Speiser, … M. F. Bachmann·bioRxiv·Apr 24, 2021